Navigation Links
Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Date:6/16/2008

mers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
3. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
4. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
11. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   ICD-10 Charts ... months of development, it has officially launched its ... Charts Training Academy and the new 4 Step ... well as all other ICD-10 Charts resources and ... in America, completely free-of-charge.  With the release of ...
(Date:7/7/2015)... 2015 Research and ... the "Elemental Analysis Market by Type (Organic, ... Application (Life Sciences, Food and Beverage Testing, Environment ... report to their offering. The ... types, technologies, and applications. By type, the market ...
(Date:7/7/2015)... and FREMONT, Calif. , July 7, ... South Korea and Velos, Inc. have entered into ... eResearch for cancer research nationally throughout South Korea ... The recent agreement signing was accompanied by a two day ... , South Korea.  National Cancer Center President ...
Breaking Medicine Technology:ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4Elemental Analysis (Organic, Inorganic) Market 2015 - Analysis & Global Forecasts to 2020 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 3
... Oct. 6 According to Millennium Research Group ... intelligence, growth in the $2 billion US cardiac ... the expanded approval of Boston Scientific,s chronic resynchronization ... I and II patients. The New ...
... Oct. 6 e-MDs, an industry leader in ... (EHRs) and practice management (PM) solutions,  congratulates  the ... Family Medicine of Fort Collins, CO, for their ... of Excellence recipients.  The Healthcare Information and Management ...
Cached Medicine Technology:Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
(Date:7/7/2015)... ... ... Ticket Down is a reputable source of authentic tickets for the 2015 CONCACAF Gold Cup ... at the Toyota Stadium. , The 2015 CONCACAF Gold Cup is now upon us ... held on American soil, will kick off in Frisco, CA from the Toyota Stadium and ...
(Date:7/7/2015)... ... , ... The United States Centers for Disease Control and Prevention have awarded ... Multicultural AIDS Coalition $3.78 million for a five-year HIV prevention partnership that will ... transgender women, the groups at highest risk of HIV infection in the US. ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... group whose board is limited to permit holders. The Medical Cannabis Alliance of ... move the industry forward and are committed to making sure patients have access ...
(Date:7/7/2015)... , ... July 07, 2015 , ... Safe Catch is ... single fish for mercury. Albertsons, Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers Market ... , “We developed the technology to test every fish for mercury,” said Safe Catch ...
(Date:7/7/2015)... ... 07, 2015 , ... On Saturday, May 16th, 2015, the Manistee, MI chapter ... Country Club. Best Drug Rehabilitation staff members were delighted to join in for this ... International, the parent of the Manistee Kiwanis Club, is a global organization that works ...
Breaking Medicine News(10 mins):Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2
... negative (benign) MRI-guided vacuum assisted breast biopsy may not be ... Yale New Haven Hospital in Connecticut, included 144 patients with ... 36 months. The study found no malignancies on follow-up ... of the study. Two patients had suspicious findings at follow-up ...
... HealthDay Reporter , THURSDAY, May 3 (HealthDay News) ... that regardless of how "full" a person may feel, ... overeating when tempted by yummy foods. The study ... eight participants, and the authors acknowledge that their findings ...
... be a primary cause of uncontrollable tumor growth in some ... authors, findings run counter to widely accepted beliefs that genetic ... or low oxygen levels in cells, is proven to be ... for curing the malignant growth could change in significant ways, ...
... Researchers at Albert Einstein College of Medicine of ... that levels of certain related proteins found in blood are associated ... up to a decade or more later. The findings, published ... a new front in the war against diabetes. These ...
... HealthDay Reporter , THURSDAY, May 3 (HealthDay News) -- When ... inflammation, and during the first 10 years with the disease ... kidney problems. Because kidney inflammation (also called lupus nephritis) ... of Rheumatology has issued new guidelines for the screening and ...
... presentations that will be given by researchers from ... American Psychiatric Association (APA) annual meeting in Philadelphia ... Lawrence C. Kolb Professor and chairman of the ... and NewYork-Presbyterian Hospital/Columbia and director of the New ...
Cached Medicine News:Health News:Why You Overeat Even When You're Full 2Health News:Why You Overeat Even When You're Full 3Health News:Low oxygen levels could drive cancer growth 2Health News:Low oxygen levels could drive cancer growth 3Health News:Study identifies possible protective blood factors against Type 2 diabetes 2Health News:New Guidelines Issued for Severe Lupus 2Health News:New Guidelines Issued for Severe Lupus 3Health News:Columbia University Medical Center and NY-Presbyterian experts at APA meeting 2Health News:Columbia University Medical Center and NY-Presbyterian experts at APA meeting 3
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: